← Eichor
Study identifier: NCT03845205 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

Condition: Alcohol Use Disorder · Alcoholic Hepatitis  ·  Sponsor: Johns Hopkins University

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant period to optimize patient outcomes. The proposed randomized clinical trial will examine the implementation and effects of integrated, person- and computer-delivered alcohol treatment compared to standard care on alcohol use (assessed by self-report and biomarker), mood, quality of life and survival following AH-LT. Predictors of 12-month post-transplant alcohol outcomes will be explored to allow future improved tailoring and targeting of these treatments.

This description comes directly from the study's public registry record.

Talk to the study team

MARY E MCCAUL, PhD  ·  410-955-9526  ·  mmccaul1@jhmi.edu

Victor Chen, MD  ·  410-550-1793  ·  pchen37@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins University School of MedicineBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03845205